RXST Deadline: RXST Investors with Losses in Excess of $100K Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit

prnewswire

RXST Deadline: RXST Investors with Losses in Excess of $100K Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit – NEWSnet – News… as it used to be

More Press Releases

June 30, 2026

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

June 30, 2026

Corient Accelerates European Growth With the Addition of Letus Private Office

June 30, 2026

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

June 30, 2026

RXST Deadline: RXST Investors with Losses in Excess of $100K Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

Corient Accelerates European Growth With the Addition of Letus Private Office

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

“BOCCHI THE ROCK!” SeisyunComplex Premiered on June 20!